Other

Recommendations for the use of meningococcal vaccines in South Africa

Published in: Southern African Journal of Infectious Diseases
Volume 32 , issue 3 , 2017 , pages: 82–86

DOI: 10.1080/23120053.2017.1359939

Author(s): Susan Meiring Division of Public Health Surveillance and Response, South Africa , Gregory Hussey Vaccines for Africa Initiative, Institute for Infectious Diseases and Molecular Medicine, South Africa , Prakash Jeena Department of Paediatrics, South Africa , Salim Parker General Practitioner, South African Society of Travel Medicine, South Africa , Anne von Gottberg Centre for Respiratory Diseases and Meningitis, South Africa

Keywords: guidelines , meningitis , meningococcal vaccines , Neisseria meningitidis , South Africa , vaccine

Download full text Get new issue alerts

Abstract

Background: Although meningococcal disease (MD) incidence in South Africa is low, Neisseria meningitidis (NM) causes severe disease that is often life-threatening and can cause long-term disabilities. A quadrivalent protein-conjugated meningococcal vaccine (MCV4) is available, and provides protection against 75% of disease causing serogroups in South Africa.

« Hepatitis C virus seroprevalence among haemodialysis patients, sickle cell patients and blood donors at a tertiary hospital in Yaounde, Cameroon

The recovery and molecular identification of HAdV-D17 in raw sewage and mussel samples collected in the Eastern Cape province of South Africa »